Mylan acquires generics business of Merck KGaA

Mylan says it will benefit from substantial operational efficiencies and economies of scale from increased sales volumes and its vertically and horizontally integrated platform.

The deal makes Mylan the third largest generic company worldwide, employing more than 11,000 people and the company now has a global presence in more than 90 countries. The company now has more than 570 products and the world’s second largest portfolio of active pharmaceutical ingredients with 126 US drug master files.

Robert Coury, Mylan’s vice chairman and CEO, said: “The new Mylan now has all of the critical attributes we need to ensure future success and deliver powerful growth. We have enhanced scale and stability, a truly global reach, vertical and horizontal integration, and breadth and depth in our management team. Most importantly, we have a common purpose and dedication to executing on our strategy and delivering superior shareholder returns.”